Published online October 30, 2006
PEDIATRICS Vol. 118 No. 6 December 2006, pp. e1696-e1700 (doi:10.1542/peds.2006-0604)

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Diamanti, A. Articles by Castro, M. Search for Related Content PubMed PubMed Citation Articles by Diamanti, A. Articles by Castro, M. Related Collections Gastrointestinal Tract Social Bookmarking                         What's this?

ARTICLE

Clinical Value of Immunoglobulin A Antitransglutaminase Assay in the Diagnosis of Celiac Disease

Antonella Diamanti, MD^a, Franco Colistro, MD^b, Angelica Calce, PhD^a, Rita Devito, MD^c, Francesca Ferretti, MD^a, Antonio Minozzi, PhD^b, Alexandra Santoni, PhD^b and Massimo Castro, MD^a

^a Gastroenterology and Nutrition Unit
^b Biochemistry Laboratory
^c Pathology Service, Pediatric Hospital "Bambino Gesù," Rome, Italy

OBJECTIVES. Our goal was to evaluate the possible correspondence between antitissue transglutaminase of immunoglobulin A class levels and stage of mucosal damage in patients affected by celiac disease. In addition, we assessed clinical use of antitissue transglutaminase values to predict biopsy results.

METHODS. One thousand eight hundred eighty-six consecutive patients with symptoms suggestive of celiac disease and 305 healthy controls underwent determination of serum levels of immunoglobulin A and antitissue transglutaminase. An intestinal biopsy was performed in subjects with antitissue transglutaminase levels 4 IU/mL and in subjects with negative antitissue transglutaminase levels but with clinical suspicion of celiac disease. Histologic grading of celiac disease was consistent with the Marsh classification.

RESULTS. One hundred eighty-six subjects with positive antitissue transglutaminase levels and 91 patients with negative antitissue transglutaminase levels were submitted to biopsy. In all healthy subjects, antitissue transglutaminase results were negative. Histologic evaluations in patients with positive antitissue transglutaminase levels gave the following results: type 0 in 25 patients, type 1 in 3 patients, type 2 in 4 patients, type 3a in 22 patients, type 3b in 74 patients, and type 3c in 58 patients. None of the patients with negative antitissue transglutaminase levels showed histologic findings suggestive of celiac disease. The mean antitissue transglutaminase values in patients without mucosal atrophy were significantly lower than in patients with mucosal atrophy. Antitissue transglutaminase values 20 IU/mL were found in only 1 patient without mucosal atrophy.

CONCLUSIONS. Our study found a strong correspondence between antitissue transglutaminase levels and stage of mucosal injury; antitissue transglutaminase values >20 IU/mL seemed to be strongly predictive of mucosal atrophy.

---

Key Words: celiac disease • antitissue transglutaminase • Marsh classification

Abbreviations: CD—celiac disease • Ig—immunoglobulin • EMA—antiendomysial antibodies of immunoglobulin A class • tTG—antitissue transglutaminase of immunoglobulin A class • PPV—positive predictive value • NPV—negative predictive value

---

Accepted Jun 12, 2006.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?